Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes of Toxoplasma gondii Against Acute and Chronic Toxoplasmosis in Mice

Frickel, 2008, Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes, J Infect Dis., 198, 1625, 10.1086/593019

El, 2014, Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice, Vaccine, 32, 3243, 10.1016/j.vaccine.2014.03.092

Innes, 2010, Vaccination against Toxoplasma gondii: an increasing priority for collaborative research, Expert Rev Vaccines, 9, 1117, 10.1586/erv.10.113

Smith, 2013, Applications of nanotechnology for immunology, Nat Rev Immunol., 13, 592, 10.1038/nri3488

Smith, 2015, Nanoparticles as synthetic vaccines, Curr Opin Biotechnol., 34, 217, 10.1016/j.copbio.2015.03.014

Rodríguez-Limas, 2013, Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development, Curr Opin Biotechnol., 24, 1089, 10.1016/j.copbio.2013.02.008

Kushnir, 2012, Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development, Vaccine, 31, 58, 10.1016/j.vaccine.2012.10.083

Bellier, 2013, Virus-like particle-based vaccines against hepatitis C virus infection, Expert Rev Vaccines, 12, 143, 10.1586/erv.13.10

Geldmacher, 2004, An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice, Virology, 323, 108, 10.1016/j.virol.2004.02.022

Roose, 2013, Hepatitis B core-based virus-like particles to present heterologous epitopes, Expert Rev Vaccines, 12, 183, 10.1586/erv.12.150

Tan, 2010, Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans, Vaccine, 28, 3977, 10.1016/j.vaccine.2010.03.028

Brown, 1995, Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis, Immunology, 85, 419

Henriquez, 2010, Immunogenetics of Toxoplasma gondii informs vaccine design, Trends Parasitol., 26, 550, 10.1016/j.pt.2010.06.004

Blanchard, 2008, Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum, Nat Immunol., 9, 937, 10.1038/ni.1629

Velge-Roussel, 2001, Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines, Parasitology, 123, 225, 10.1017/S0031182001008460

Godard, 1994, Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis, Mol Immunol., 31, 1353, 10.1016/0161-5890(94)90054-X

Graille, 2005, Crystal structure of the complex between the monomeric form of Toxoplasma gondii surface antigen 1 (SAG1) and a monoclonal antibody that mimics the human immune response, J Mol Biol, 354, 447, 10.1016/j.jmb.2005.09.028

Siachoque, 2006, Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model, Exp Parasitol., 114, 62, 10.1016/j.exppara.2006.02.005

Cardona, 2009, Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis, Exp. Parasitol., 123, 199, 10.1016/j.exppara.2009.06.017

Grover, 2012, The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden, Infect Immun., 80, 3279, 10.1128/IAI.00425-12

Howe, 1995, Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease, J Infect Dis., 172, 1561, 10.1093/infdis/172.6.1561

Melo, 2011, Toxoplasma gondii effectors are master regulators of the inflammatory response, Trends Parasitol., 27, 487, 10.1016/j.pt.2011.08.001

Shen, 2014, Toxoplasma aldolase is required for metabolism but dispensable for host-cell invasion, Proc Natl Acad Sci U S A., 111, 3567, 10.1073/pnas.1315156111

Zhou, 2016, Metabolomic profiling of mice serum during toxoplasmosis progression using liquid chromatography-mass spectrometry, Sci Rep, 6, 19557, 10.1038/srep19557

Sockolosky, 2013, Periplasmic production via the pET expression system of soluble, bioactive human growth hormone, Protein Expr Purif., 87, 129, 10.1016/j.pep.2012.11.002

Lin, 2012, CεmX peptide-carrying HBcAg virus-like particles induced antibodies that down-regulate mIgE-B lymphocytes, Mol Immunol., 52, 190, 10.1016/j.molimm.2012.05.015

Bin, 2017, Yield optimisation of Hepatitis B virus core particles in E. coli expression system for drug delivery applications, Sci Rep, 7, 43160, 10.1038/srep43160

Qian, 2017, Immune complex negatively regulates toll-like receptor 3-triggered tumour necrosis factor α production in B cells, Cent Eur J Immunol, 42, 223, 10.5114/ceji.2017.70962

Newman, 2003, Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins, J Virol., 77, 12950, 10.1128/JVI.77.24.12950-12960.2003

Skrastina, 2008, High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers, Vaccine, 26, 1972, 10.1016/j.vaccine.2008.02.030

Dimier-Poisson, 2015, Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection, Biomaterials, 50, 164, 10.1016/j.biomaterials.2015.01.056

Guo, 2018, Chitosan microsphere used as an effective system to deliver a linked antigenic peptides vaccine protect mice against acute and chronic toxoplasmosis, Front Cell Infect Microbiol, 8, 163, 10.3389/fcimb.2018.00163

Cui, 2012, Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis, Vaccine, 30, 2282, 10.1016/j.vaccine.2012.01.073

Zheng, 2013, The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against toxoplasmosis in mice, Vaccine, 31, 4578, 10.1016/j.vaccine.2013.07.058

Zlotnick, 1996, Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein, Biochemistry, 35, 7412, 10.1021/bi9604800

Seeger, 2000, Hepatitis B virus biology, Microbiol Mol Biol Rev., 64, 51, 10.1128/mmbr.64.1.51-68.2000

Whitacre, 2009, Use of hepadnavirus core proteins as vaccine platforms, Expert Rev Vaccines, 8, 1565, 10.1586/erv.09.121

Dryden, 2006, Native hepatitis B virions and capsids visualized by electron cryomicroscopy, Mol Cell, 22, 843, 10.1016/j.molcel.2006.04.025

Ravin, 2015, Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency, Vaccine, 33, 3392, 10.1016/j.vaccine.2015.04.066

Peyret, 2015, Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins, PLoS ONE, 10, e0120751, 10.1371/journal.pone.0120751

Yin, 2014, Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine, Immunobiology, 219, 97, 10.1016/j.imbio.2013.08.008

Skwarczynski, 2016, Peptide-based synthetic vaccines, Chem Sci, 7, 842, 10.1039/c5sc03892h

Correa, 2007, Congenital and acquired toxoplasmosis: diversity and role of antibodies in different compartments of the host, Parasite Immunol., 29, 651, 10.1111/j.1365-3024.2007.00982.x

Sayles, 2000, B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii, Infect Immun., 68, 1026, 10.1128/IAI.68.3.1026-1033.2000

Zheng, 2017, Immuno-Efficacy of a T. gondii secreted protein with an altered thrombospondin repeat (TgSPATR) As a Novel DNA Vaccine Candidate against Acute Toxoplasmosis in BALB/c Mice, Front Microbiol, 8, 216, 10.3389/fmicb.2017.00216

Zhang, 2014, Prediction of conformational B-cell epitopes, Methods Mol Biol., 1184, 185, 10.1007/978-1-4939-1115-8

Denkers, 1998, Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection, Clin Microbiol Rev., 11, 569, 10.1128/CMR.11.4.569

Filisetti, 2004, Immune response to Toxoplasma gondii, Ann Ist Super Sanita, 40, 71, 10.1093/intimm/dxy004

Ching, 2016, Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB/c Mice, Front Microbiol, 7, 609, 10.3389/fmicb.2016.00609

Sonaimuthu, 2016, Induction of protective immunity against toxoplasmosis in BALB/c mice vaccinated with Toxoplasma gondii Rhoptry-1, Front Microbiol, 7, 808, 10.3389/fmicb.2016.00808

Lecordier, 1995, Characterization of a dense granule antigen of Toxoplasma gondii (GRA6) associated to the network of the parasitophorous vacuole, Mol Biochem Parasitol., 70, 85, 10.1016/0166-6851(95)00010-X

Hajj, 2006, Characterization, biosynthesis and fate of ROP7, a ROP2 related rhoptry protein of Toxoplasma gondii, Mol Biochem Parasitol., 146, 98, 10.1016/j.molbiopara.2005.10.011

Soête, 1994, Experimental induction of bradyzoite-specific antigen expression and cyst formation by the RH strain of Toxoplasma gondii in vitro, Exp Parasitol., 78, 361, 10.1006/expr.1994.1039

Luo, 2017, Induction of Protective Immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) Self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP), Front Microbiol, 8, 605, 10.3389/fmicb.2017.00605

Gazzinelli, 1996, In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha, J Immunol., 157, 798, 10.4049/jimmunol.157.2.798

Desolme, 2000, Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene, Vaccine, 18, 2512, 10.1016/s0264-410x(00)00035-9

Chen, 2014, Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice, BMC Infect Dis., 14, 487, 10.1186/1471-2334-14-487

Wang, 2017, Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice, Front Immunol, 8, 730, 10.3389/fimmu.2017.00730

Wang, 2017, Major immunodominant region of Hepatitis B virus core antigen as a delivery vector to improve the immunogenicity of the fusion antigen ROP2-SAG1 multiepitope from Toxoplasma gondii in Mice, Viral Immunol., 30, 508, 10.1089/vim.2016.0135